STAT

APRIL 24, 2023

Marburg could soon become the second virus in the past year to have experimental vaccine candidates ready for testing under an emergency use listing. Until this point, no licensed vaccines or treatments are available for Marburg. With the whole region on high alert, a safe and effective vaccine really couldn’t come soon enough.

Vaccines 255

Vaccines 255

STAT

AUGUST 27, 2024

In early 2022, I cared for one of the first patients with mpox in Massachusetts. As an infectious diseases physician, I remember the deep uncertainty I felt, and the fear in my patient’s eyes as a painful rash spread over their body.

Vaccines 357

Vaccines 357

STAT

AUGUST 23, 2024

The comments came in response to an article  The Financial Times  that claimed the company is considered changing the location of a $578 million vaccine manufacturing plant from Liverpool to Philadelphia because the new U.K. and Japan, and have been in widespread use for mpox since 2022. to the U.S.

Vaccines 249

Vaccines Packaging 249

STAT

MARCH 17, 2023

Bancel made $398 million in 2022 based on the actual realized gains of stock that was exercised and sold, according to STAT’s calculations from Moderna’s annual compensation disclosure filed this week.

Vaccines 285

Vaccines 285

STAT

SEPTEMBER 30, 2022

The shortlist includes researchers who elucidated how cells make energy, those who discovered the chemical chatter of bacteria, many of the brilliant minds who shepherded us into the “ era of the genome ,” and most prominently, the pioneers behind the mRNA Covid vaccines. Read the rest…

Vaccines 291

Vaccines 291

STAT

SEPTEMBER 9, 2022

As the promotional push to get people vaccinated with one of the updated, bivalent Covid vaccines heats up, federal health authorities are urging Americans to consider getting their Covid shot and their flu shot at the same time. ” — Ashish Jha, White House Covid coordinator, Sept.

Vaccines 312

Vaccines 312

STAT

JANUARY 31, 2024

In 2022, it supported a petition before the World Trade Organization to gut intellectual property protections for Covid-19 vaccines. The Biden administration may soon double down on one of its gravest mistakes.

Vaccines 342

Vaccines 342

STAT

APRIL 6, 2023

The wholly synthetic mRNA vaccines for Covid-19 saved nearly 20 million lives in just their first year of use, according to data published in 2022 by The Lancet. Some of these efforts will succeed, and some surely will fail. But it is hardly hype to call what is happening in labs around the world a revolution in biology.

Vaccines 307

Vaccines 307

STAT

SEPTEMBER 23, 2024

WASHINGTON — Of the roughly 15 million Americans who tried to quit smoking in 2022, 5 in 6 failed. Look at Covid, how many vaccines do we have?” It’s a jarring statistic — and an indictment of the treatment options for an addiction that kills 480,000 people in the U.S.

Vaccines 351

Vaccines Drug Development 351

STAT

APRIL 9, 2024

This is the largest amount raised since the first half of 2022 — and big news for an industry that has been icy for the last three years, once the attention the Covid pandemic brought to drug companies began to fade. Layoffs became commonplace. The company plans to submit the data to the U.S.

Vaccines 194

Vaccines 194

STAT

APRIL 19, 2023

In the fall of 2022, a tidal wave of respiratory viral illnesses sent children to emergency rooms in droves when enterovirus, respiratory syncytial virus (RSV), and influenza peaked in close succession, bombarding young children who had remained mostly unexposed to these viruses during the most acute years of the Covid pandemic.

Vaccines 225

Vaccines Hospitals 225

Pharmaceutical Technology

FEBRUARY 21, 2023

Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, had a phenomenal year with forecast sales of $37bn in 2022. Comirnaty is the leading prophylactic vaccine for Covid-19 and is expected to generate an additional $2.8bn in sales in 2022 compared to GlobalData’s H1 2022 forecast.

Vaccines 98

Vaccines 98

STAT

SEPTEMBER 26, 2024

Pfizer acquired the company that made Oxbryta, a biotech called Global Blood Therapeutics, in 2022 for $5.4 A legal battle between Pfizer and Moderna over their rival Covid-19 vaccines will continue after London’s High Court on Wednesday gave Pfizer permission to take the case to the Court of Appeal, Reuters writes.

Vaccines 243

Vaccines 243

pharmaphorum

MAY 19, 2022

Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt. There are hopes that its mRNA approach, which proved so effective against COVID-19, could succeed where traditional vaccine technologies have failed in HIV.

Vaccines 145

Vaccines Immunity Immunization 145

European Pharmaceutical Review

AUGUST 10, 2022

On 23 July 2022, the World Health Organization (WHO) Director-General, Dr Tedros Adhanom Ghebreyesus, declared the multi-country outbreak of monkeypox a public health emergency of international concern. countries with manufacturing capacity for diagnostics, vaccines and therapeutics. But what is monkeypox? Current case rates.

Vaccines 96

Vaccines Immunization Immunity Labelling 96

European Pharmaceutical Review

JANUARY 16, 2023

This Q&A covers the key developments in pharmaceutical microbiology in 2022, featuring insight from pharmaceutical microbiology experts: Dr Tim Sandle, Head of Microbiology, Bio Products Laboratory Limited. Regulation, particularly Annex 1, was identified as a key focus for 2022.

Vaccines 128

Vaccines Research Laboratories Documentation Compounding 128

STAT

OCTOBER 11, 2022

At their January 2022 peak, Covid-19 hospitalizations were more than five times higher across all age groups compared with kids, even though kids have far lower Covid-19 vaccination rates than adults.

Hospitals 243

Hospitals Vaccines 243

pharmaphorum

JANUARY 5, 2022

The year 2020 ended on a note of hope, with the 8th December vaccination of 91-year-old Margaret Keenan, the world’s first person to receive a COVID-19 vaccine outside clinical trials. Add to this the fact that the world missed the WHO targets for global vaccination by the end of 2021 and will likely continue to miss targets in 2022.

HIV Treatment and Prevention Agents 98

HIV Treatment and Prevention Agents Vaccines 98

pharmaphorum

JUNE 21, 2021

It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on cancer vaccines, before being catapulted onto the world-stage with its COVID-19 shot. Among the 25-strong group given the vaccine on its own, there was one patient who had a complete remission of tumours that had spread from the original site.

Vaccines 145

Vaccines Immunity Immunization 145

Express Pharma

JULY 2, 2024

Techinvention Lifecare has been appointed as a consultant by Botswana Vaccine Institute (BVI) to monitor setting up of the new cGMP compliant, vaccine manufacturing unit in its existing facility at Gaborone, Botswana. The project commenced in 2022 and is expected to be completed and operational by 2026.

Vaccines 111

Vaccines 111

Pharma Times

DECEMBER 14, 2021

The public have been assured more sites, mobile units and pop-ups would be set up across the country to fulfill the vaccination pledge ahead of the original deadline of 31 January 2022.

Vaccines 119

Vaccines 119

European Pharmaceutical Review

DECEMBER 22, 2022

has finalised a strategic partnership with the UK government to establish a state-of-the-art mRNA vaccine research, development, and manufacturing facility in the UK. This milestone follows the agreement in principle between Moderna and the UK Government, announced in June 2022. Moderna, Inc.

Vaccines 131

Vaccines 131

STAT

OCTOBER 10, 2023

The state’s biotech scene   exploded in the mid-2010s and early in the pandemic as exuberant investors disregarded the high failure rate in drug development and bet on buzzy technologies such as gene editing and messenger RNA vaccines. But the   drumbeat of layoffs in 2022   has only grown louder this year.

Vaccines 339

Vaccines Generic Medicine Drug Development Packaging 339

pharmaphorum

DECEMBER 4, 2020

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets.

Vaccines 119

Vaccines Immunity Immunization 119

European Pharmaceutical Review

NOVEMBER 1, 2023

In July 2022, the World Health Organization (WHO) released its inaugural report on the pipeline of vaccines currently in development to prevent infections caused by antimicrobial resistance (AMR) bacterial pathogens. WHO referred to 61 bacterial vaccine candidates in diverse stages of clinical development.

Vaccines 115

Vaccines Immunization Immunity Drug Development 115

Pharmaceutical Technology

MARCH 28, 2023

Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. In its FY 2022 report, BioNTech has identified herpes simplex virus (HSV), malaria, and shingles as disease targets. However, following its launch of the world’s first Omicron BA.4/BA.5

Vaccines 110

Vaccines 110

pharmaphorum

FEBRUARY 9, 2022

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. One area that is gathering increasing levels of interest is the development of cancer vaccines. A broad front.

Vaccines 134

Vaccines Immunity Immunization Labelling 134

Pharmaceutical Technology

MAY 11, 2023

Results published in Nature for a personalised pancreatic cancer vaccine that uses neoantigens from patients’ tumours have lent further support to early positive signals. The vaccine, developed by BioNTech, led to half of the patients with pancreatic cancer in the Phase I trial remaining cancer-free 18 months later.

Vaccines 138

Vaccines Immunity Immunization 138

Express Pharma

JUNE 26, 2024

The success of the COVID-19 mRNA vaccines highlighted the major advantages of utilising mRNA technology in vaccine development. Consequently, the FDA has awarded a rising number of review designations to mRNA vaccines in recent years. Implementation of these vaccines is estimated to have prevented 14.4

Vaccines 111

Vaccines Immunity Immunization 111

ALiEM - Pharm Pearls

JANUARY 12, 2024

A 42-year old Bengali man with a history of hyperlipidemia presented to the Emergency Department with facial swelling, diffuse rash, renal insufficiency and proteinuria after receiving his COVID-19 vaccine (Moderna) booster dose. Erythema multiforme has been reported as a cutaneous reaction after the COVID-19 mRNA vaccine.

Vaccines 130

Vaccines 130

Pharmaceutical Technology

DECEMBER 27, 2022

The healthcare industry saw its share of ups and downs in 2022. Reynald Castaneda wrote about the affected clinical trial ecosystems in both countries , while Fiona Barry and Manasi analysed the impact of the war on the supply of the Russian Covid-19 vaccine Sputnik V to the rest of the world. Tracking the diversity push.

Vaccines 122

Vaccines Drug Development Drug Pricing 122

Pharma Times

DECEMBER 15, 2023

The funding builds on AstriVax’s €30m in seed funding for its vaccine platform AstriVax has announced that it has been awarded a total of €3m in funding from Flanders Innovation & Entrepreneurship (VLAIO) for its therapeutic vaccine targeting chronic hepatitis B. in May to advance the company’s innovative vaccine platform.

Vaccines 119

Vaccines 119

European Pharmaceutical Review

MARCH 27, 2023

percent between 2022 and 2027. The research includes historic market data from 2017 to 2021, using 2022 as the base year. In the report, analysts showed North America was the largest revenue contributor to the global rapid microbiology testing market in 2022, with the US being the leading country. Don Whitley Scientific Ltd.,

Compounding 115

Compounding Vaccines 115

European Pharmaceutical Review

DECEMBER 21, 2022

Messenger RNA (mRNA) as a drug modality has been propelled into the limelight due to the recent success of mRNA-based vaccines. However, the potential of mRNA therapies, which deliver custom‑designed mRNA into a target cell where the cellular machinery translates it into a functional protein, extends far beyond viral vaccines.

Vaccines 97

Vaccines 97

European Pharmaceutical Review

MAY 9, 2024

Withdrawal of the marketing authorisation for the COVID-19 vaccine (ChAdOx1-S [recombinant]) Vaxzevria (SRD) by the European Medicines Agency on 7 May, follows a request by AstraZeneca. Global demand for all COVID vaccines is now much lower and overall supply exceeds demand.

Vaccines 110

Vaccines 110

STAT

DECEMBER 13, 2024

Specifically, the amount spent on basic research, new treatments, vaccines, and diagnostics was $1.2 billion, the highest level since tracking of funding began in 2005 and 20% more than what was seen in 2022.

Pharmaceutical Companies 244

Pharmaceutical Companies Pharmaceutical Companies Vaccines Drug Pricing 244

European Pharmaceutical Review

AUGUST 2, 2023

A new COVID-19 vaccine has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). Bimervax is now the ninth vaccine to be authorised by the UK’s independent medicines regulator to treat the virus. The vaccine demonstrated a strong immune response in the trial.

Vaccines 98

Vaccines Immunization Immunity 98